VIDEO: Subanalyses focus on pegcetacoplan results in geographic atrophy treatment
Key takeaways:
- One post hoc analysis showed eyes treated with pegcetacoplan were slower progressors.
- Pegcetacoplan may also contribute to tissue preservation.
NEW ORLEANS — In this Healio Video Perspective from the ARVO meeting, Allen Chiang, MD, discusses three subanalyses from the DERBY and OAKS studies of pegcetacoplan for the treatment of geographic atrophy.
“In the latter part of the 18-month to 24-month part of the clinical trial data, we saw that the lesion growth reduced by a greater amount, by 30%, in monthly treated eyes vs. 24% in the every other month treated eyes vs. sham,” Chiang said. “So, that is a concept that is important.”
In addition to reviewing the topline data for pegcetacoplan, the analysis “unpacks what was approved, and it shows that staying on treatment is really important. I think that’s a take home,” he said.
Collapse
Chiang A, et al. Assessment of geographic atrophy (GA) lesion progression in the phase 3 OAKS and DERBY trials. Presented at: Association for Research in Vision and Ophthalmology meeting; April 23-27, 2023; New Orleans.
Read more about